Occurrence of AML in cells of donor origin after treatment of CML in relapse with imatinib and donor stem cell boost 16 years after the original allogeneic BMT.

摘要

The occurrence of donor-derived AML is a rare event after allogeneic BMT, which on occasion can develop as a de novo secondary hematologic malignancy within a general susceptibility of secondary cancer after BMT. Furthermore, transmission of hematologic disturbances of donor origin has to be taken into consideration.